NLRP3 Inflammasome Inhibition by the Novel Bispecific Antibody InflamAb Attenuates Atherosclerosis in Apolipoprotein E–Deficient Mice

The NLRP3 inflammasome contributes to the inflammatory process in atherosclerosis by producing IL-1β. Components of the intracellular NLRP3 inflammasome have been shown to be expressed by macrophages in the atherosclerotic plaque and are a potential therapeutic target. We aimed to determine the efficacy of the novel bispecific antibody InflamAb, designed to target the interleukin-1 receptor type 1 and the NLRP3 inflammasome, in inhibiting atherosclerosis. InflamAb effectively inhibited IL-1β secretion from bone marrow-derived macrophages and reduced circulating IL-1β levels in vivo. Furthermore, InflamAb treatment significantly inhibited atherosclerotic plaque development, accompanied by a reduction in relative macrophage and necrotic core content. InflamAb treatment did not affect the size of established atherosclerotic lesions; however, InflamAb significantly reduced relative macrophage and necrotic core content in these plaques. To conclude, inhibition of the NLRP3 inflammasome by the bispecific antibody InflamAb shows promising efficacy in inhibiting atherosclerotic plaque development and destabilization in Apoe<sup>-/-</sup> mice.

Authors

Institutions

Publication Details

Journal
JACC Basic to Translational Science
Published
2025-03-05
DOI
https://doi.org/10.1016/j.jacbts.2024.12.012
Citations
4
Primary Topic
Inflammasome and immune disorders
Type
article
Field-Weighted Citation Impact
3.22

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

NLRP3 Inflammasome Inhibition by the Novel Bispecific Antibody InflamAb Attenuates Atherosclerosis in Apolipoprotein E–Deficient Mice

Amanda C. Foks, Meredith Gregory‐Ksander, Johan Kuiper, Lucie Delfos et al.
4 citations
JACC Basic to Translational Science
Inflammasome and immune disorders
3.22
article

NLRP3 Inflammasome Inhibition by the Novel Bispecific Antibody InflamAb Attenuates Atherosclerosis in Apolipoprotein E–Deficient Mice

Amanda C. Foks, Meredith Gregory‐Ksander, Johan Kuiper, Lucie Delfos, Melody Chemaly, Rebecca C. Coll, Christopher Power, Victoria McGilligan, Aaron Peace, Sophie Coyle, Marie A.C. Depuydt, Frank H. Schaftenaar, Ilze Bot, Mireia N. A. Bernabé Kleijn, Peter J. van Santbrink, Pier Pieterszoon Lindenbergh, C. Costello
article en
4 citations

Abstract

The NLRP3 inflammasome contributes to the inflammatory process in atherosclerosis by producing IL-1β. Components of the intracellular NLRP3 inflammasome have been shown to be expressed by macrophages in the atherosclerotic plaque and are a potential therapeutic target. We aimed to determine the efficacy of the novel bispecific antibody InflamAb, designed to target the interleukin-1 receptor type 1 and the NLRP3 inflammasome, in inhibiting atherosclerosis. InflamAb effectively inhibited IL-1β secretion from bone marrow-derived macrophages and reduced circulating IL-1β levels in vivo. Furthermore, InflamAb treatment significantly inhibited atherosclerotic plaque development, accompanied by a reduction in relative macrophage and necrotic core content. InflamAb treatment did not affect the size of established atherosclerotic lesions; however, InflamAb significantly reduced relative macrophage and necrotic core content in these plaques. To conclude, inhibition of the NLRP3 inflammasome by the bispecific antibody InflamAb shows promising efficacy in inhibiting atherosclerotic plaque development and destabilization in Apoe<sup>-/-</sup> mice.

JACC Basic to Translational ScienceVol. 10(6)
Leiden University (NL), Massachusetts Eye and Ear Infirmary (US), University of Ulster (GB), Derry City Council (GB), Wellcome Trust Centre for the History of Medicine (GB), Western Health and Social Care Trust (GB), Centre for Human Drug Research (NL), China Power Engineering Consulting Group (China) (CN), University College London (GB)
Ulster University, Universiteit Leiden, Hartstichting
Openalex Percentile: Top 9%
Inflammasome and immune disorders
3.22
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.